We're geared to launch a new molecule every 1-2 years: Biocon Biologics MD

In an interview, Arun Chandavarkar explains why a company must continue investing in R&D despite the impact on short-term Ebitda

The market share that Biocon Biologics' insulin Glargine injection has gained in the US has been partially offset by price erosion in the company's key products. In an interview, Arun Chandavarkar, MD, Biocon Biologics explains to Sohini Das why a company must continue investing in R&D even if that affects short-term Ebitda. Edited excerpts:

You have gained market share in the US for your insulin Glargine injections. What is